Time to Castration Resistance is a Novel Prognostic Factor of Cancer-specific Survival in Patients with Nonmetastatic Castration-resistant Prostate Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2022 Sep 28

PMID 36171391

Authors

Yuji Hakozaki

Yuta Yamada

Taketo Kawai

Masaki Nakamura

Yuta Takeshima

Takuya Iwaki

Taro Teshima

Yoshitaka Kinoshita

Yoichi Fujii

Yoshiyuki Akiyama

Yusuke Sato

Daisuke Yamada

Motofumi Suzuki

Mayu Kashiwagi-Hakozaki

Tetsuo Ushiku

Haruki Kume

Affiliations

Soon will be listed here.

Abstract

We aimed to identify prognostic factors of cancer-specific survival (CSS) in non-metastatic castration-resistant prostate cancer (M0CRPC) patients. The final analysis of this retrospective cohort included 82 patients who were diagnosed as M0CRPC between 1998 and 2018 at the University of Tokyo Hospital. CRPC was defined as prostate-specific antigen (PSA) progression (increased PSA ≥ 25% and ≥ 2 ng/mL above the nadir or detection of a metastatic lesion). The median value of age and PSA at the time of CRPC were 76 (range 55-94) years and 2.84 (range 2.04-22.5) ng/mL, respectively. The median follow-up time from CRPC diagnosis was 38 (range 3-188) months. The prognostic factors of CSS were 'PSA doubling time (PSADT) ≤ 3 months', 'time to CRPC diagnosis from the start of androgen deprivation therapy (TTCRPC) ≤ 12 months', of which TTCRPC was a novel risk factor of CSS. In the multivariate analysis, 'PSADT ≤ 3 months' and TTCRPC ≤ 12 months' remained as statistically significant predictors of CSS. Novel risk stratification was developed based on the number of these risk factors. The high-risk group showed a hazard ratio of 4.416 (95% confidence interval 1.701-11.47, C-index = 0.727).

Citing Articles

Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance.

Gokmen I, Demir N, Peker P, Ozcan E, Akgul F, Bayrakci I Front Oncol. 2024; 14:1431629.

PMID: 39703857 PMC: 11655342. DOI: 10.3389/fonc.2024.1431629.

Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer.

Yu Y, Li L, Yang Q, Xue J, Wang B, Xie M Microorganisms. 2024; 12(8).

PMID: 39203495 PMC: 11356635. DOI: 10.3390/microorganisms12081653.

Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.

Ambrosini G, Cordani M, Zarrabi A, Alcon-Rodriguez S, Sainz R, Velasco G Cell Commun Signal. 2024; 22(1):36.

PMID: 38216942 PMC: 10790277. DOI: 10.1186/s12964-023-01462-0.

Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: An updated systematic review and meta-analysis.

Chung D, Kang D, Jung H, Lee J, Kim D, Ha J Investig Clin Urol. 2023; 64(3):242-254.

PMID: 37341004 PMC: 10172051. DOI: 10.4111/icu.20230058.

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer.

Mitsui Y, Yamabe F, Hori S, Uetani M, Aoki H, Sakurabayashi K Front Oncol. 2023; 13:1162820.

PMID: 37333829 PMC: 10272398. DOI: 10.3389/fonc.2023.1162820.

References

Howard L, Moreira D, de Hoedt A, Aronson W, Kane C, Amling C . Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017; 120(5B):E80-E86. PMC: 5617753. DOI: 10.1111/bju.13856. View

Arlen P, Bianco F, Dahut W, DAmico A, Figg W, Freedland S . Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008; 179(6):2181-5. PMC: 2667701. DOI: 10.1016/j.juro.2008.01.099. View

Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J . Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2020; 79(1):150-158. DOI: 10.1016/j.eururo.2020.08.011. View

Loriot Y, Eymard J, Patrikidou A, Ileana E, Massard C, Albiges L . Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer. 2015; 51(14):1946-52. DOI: 10.1016/j.ejca.2015.06.128. View

Miyake H, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D . Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer. Anticancer Res. 2020; 40(2):1101-1106. DOI: 10.21873/anticanres.14049. View

Uchio E, Aslan M, Wells C, Calderone J, Concato J . Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010; 170(15):1390-5. DOI: 10.1001/archinternmed.2010.262. View

Whitney C, Howard L, Freedland S, DeHoedt A, Amling C, Aronson W . Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018; 22(2):252-260. DOI: 10.1038/s41391-018-0095-0. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K . Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer. Int Urol Nephrol. 2019; 52(1):77-85. DOI: 10.1007/s11255-019-02281-4. View

10.

Choueiri T, Xie W, DAmico A, Ross R, Hu J, Pomerantz M . Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009; 115(5):981-7. PMC: 2931827. DOI: 10.1002/cncr.24064. View

11.

Moreira D, Howard L, Sourbeer K, Amarasekara H, Chow L, Cockrell D . Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016; 96:171-176. PMC: 5536963. DOI: 10.1016/j.urology.2016.06.011. View

12.

Smith M, Cook R, Lee K, Nelson J . Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011; 117(10):2077-85. PMC: 3116053. DOI: 10.1002/cncr.25762. View

13.

Chi K, Hotte S, Joshua A, North S, Wyatt A, Collins L . Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 2015; 26(10):2044-56. DOI: 10.1093/annonc/mdv267. View

14.

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

15.

Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P . Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007; 25(13):1765-71. DOI: 10.1200/JCO.2006.08.0572. View

16.

Sasaki T, Onishi T, Hoshina A . Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer. Endocr Relat Cancer. 2012; 19(5):725-30. DOI: 10.1530/ERC-12-0133. View

17.

Chung D, Ha J, Cho K . Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer. Biomedicines. 2021; 9(6). PMC: 8229358. DOI: 10.3390/biomedicines9060661. View

18.

Sternberg C, Fizazi K, Saad F, Shore N, De Giorgi U, Penson D . Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 382(23):2197-2206. DOI: 10.1056/NEJMoa2003892. View

19.

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

20.

Chandrasekar T, Yang J, Gao A, Evans C . Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2016; 4(3):365-80. PMC: 4708226. DOI: 10.3978/j.issn.2223-4683.2015.05.02. View